Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSommeijer, D.en
dc.contributor.authorKarapetis, C.en
dc.contributor.authorZalcberg, J.en
dc.contributor.authorTu, D.en
dc.contributor.authorJonker, D.en
dc.contributor.authorSimes, J.en
dc.contributor.authorTebbutt, N.en
dc.contributor.authorYip, D.en
dc.contributor.authorPrice, T.en
dc.contributor.authorO'Callaghan, C.en
dc.identifier.citationActa Oncologica, 2014; 53(7):877-884en
dc.descriptionResults were previously presented in part as a poster presentation at the 2011 Annual Meeting of the American Society of Clinical Oncology [J Clin Oncol 2011;29(Suppl; abstr 3588)].en
dc.description.abstractBACKGROUND: The NCIC CTG/AGITG CO.17 trial demonstrated that cetuximab monotherapy improved overall and progression-free survival (OS and PFS) in patients previously treated for advanced colorectal cancer. A strong relationship was observed between benefit from cetuximab and development of rash. In this analysis, the association of rash and benefit from cetuximab is explored and presented by KRAS mutation status. MATERIAL AND METHODS: Rash was graded by NCI CTC 2.0 criteria. Landmark analysis was performed by excluding patients who died or dropped out within 28 days and then grouping by worst grade of rash experienced by day 28. Multivariate Cox models were conducted separately for patients with KRAS wild-type (WT) tumours and KRAS mutated (MUT) tumours. CO.17 primary outcome was OS. RESULTS: Development of grade 2 + rash on cetuximab was associated with a trend towards increased OS (HR 0.61 with 95% CI 0.36-1.02 and p = 0.06) and PFS (HR 0.68 with 95% CI 0.45-1.03 and p = 0.07) as compared to grade 0/1 rash in patients with WT tumours. In patients with WT tumours on cetuximab both grade 0/1 and grade 2 + rash were associated with increased PFS (HR 0.57 95% CI 0.38-0.86; p = 0.008; and HR 0.32 95% CI 0.21-0.49; p < 0.0001) respectively, in comparison with best supportive care (BSC). Only development of grade 2 + rash on cetuximab was associated with increased OS (HR 0.52 with 95% CI 0.34-0.80 and p = 0.003) in comparison with BSC. No significant difference was found in OS or PFS among patients on cetuximab with MUT tumours with either rash grade as compared to BSC. No consistent trend was observed for the association of severity of rash and quality of life (QoL). CONCLUSION: As all patients with WT tumours benefitted to some extent from cetuximab regardless of the grade of rash, grade of rash was not a useful predictive marker.en
dc.description.statementofresponsibilityDirkje W. Sommeijer, Christos S. Karapetis, John R. Zalcberg, Dongsheng Tu, Derek J. Jonker, John Simes, Niall Tebbutt, Desmond Yip, Timothy J. Price, and Chris J. O’Callaghanen
dc.publisherInforma Healthcareen
dc.rights© 2014 Informa Healthcareen
dc.subjectHumans; Colorectal Neoplasms; Exanthema; ras Proteins; Proto-Oncogene Proteins; Disease-Free Survival; Treatment Outcome; Mutation; Quality of Life; Aged; Middle Aged; Female; Male; Proto-Oncogene Proteins p21(ras); Antibodies, Monoclonal, Humanized; Cetuximaben
dc.titleThe relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17en
dc.typeJournal articleen
dc.identifier.orcidPrice, T. [0000-0002-3922-2693]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.